Correspondence 0001104659-23-126114 from TriSalus Life Sciences, Inc. (TLSI)
TriSalus Life Sciences, Inc.
Date: Dec. 14, 2023 · CIK: 0001826667 · Accession: 0001104659-23-126114
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274292
Referenced dates: November 4, 2023
Letter
Carlos Ramirez
T: +1 858 550 6157
cramirez@cooley.com
December 14, 2023
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Industrial Applications and Services
100 F Street, NE
Washington, D.C. 20549
Attention:
Nicholas O’Leary
Abby Adams
Re: TriSalus Life Sciences, Inc.
Amendment No. 2 to Registration Statement on Form S-1
Filed October 19, 2023
File No. 333-274292
Ladies and Gentlemen:
On behalf of TriSalus Life Sciences, Inc. (the “Company”), we are providing this letter in response to comments (the “Comments”) received from the staff of the U.S. Securities and Exchange Commission’s Division of Corporation Finance (the “Staff”) by letter dated November 4, 2023 with respect to the Company’s Amendment No. 2 to Registration Statement on Form S-1, as filed on October 19, 2023. Concurrently with the submission of this letter, the Company is filling its third amendment to the registration statement on Form S-1 (the “Amendment No. 3”) and certain exhibits via EDGAR to the Commission.
The Staff’s comments are repeated below in bold, followed by the Company’s responses to the comments. We have included page numbers to refer to the location in Amendment No. 3 where the disclosure addressing a particular comment appears. Defined terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in Amendment No. 3.
Amendment No. 2 to Registration Statement on Form S-1 filed October 19, 2023
Cover Page
1. We note your revisions in response to prior comment 1 and we reissue in part. Please disclose here any purchase price of the assumed RSUs and legacy Trisalus shares or clarify that no consideration was paid.
In response to the Staff’s comment, the Company respectfully advises the Staff that it has revised the disclosure on the cover page and page 5 of Amendment No. 3. In response to comment 3 below, the Company has removed from registration the resale of the legacy Trisalus shares from Amendment No. 3.
Cooley LLP 10265 Science Center Drive San Diego, CA 92121-1117
t: +1 858 550 6000 f: +1 858 550-6420 cooley.com
U.S. Securities and Exchange Commission
December 14, 2023
Page Two
General
2. We note your analysis in response to prior comment 9, and reissue the comment in full. Please revise the first paragraph on the cover page, and the prospectus generally, to remove the registration of the issuance of common stock underlying the warrants referenced in the comment.
In response to the Staff’s comment, the Company respectfully advises the Staff that it has revised the disclosure on the cover page and pages 4 and 197 of Amendment No. 3 to remove from registration the issuance of common stock underlying the “Conversion Warrants” referenced in Amendment No. 3. The revised disclosure takes into account the clarification provided by the Staff pursuant to a conference call on November 7, 2023 that the Staff is only reissuing the comment for the “Conversion Warrants” and not the “Private Placement Warrants.”
3. We note your revisions to prior comment 10 and we reissue the comment. The company seeks to register “(c) up to 15,575,001 shares of Common Stock issued pursuant to that Agreement and Plan of Merger, dated as of November 11, 2022, as amended on April 4, 2023, May 13, 2023 and July 5, 2023, by and among MTAC, MTAC Merger Sub, Inc. and TriSalus Operating Life Sciences, Inc. (‘Legacy TriSalus’) to certain former equityholders of Legacy TriSalus,” as noted in the second paragraph on the cover page. As TriSalus merged into the SPAC merger subsidiary, these affiliates are deemed to be underwriters, and must set a fixed price at which the shares will be sold for the duration of the offering. Refer to Securities Act Rule 145(c). Please revise the prospectus accordingly.
In response to the Staff’s comment, the Company respectfully advises the Staff that it has revised the disclosure on the cover page and pages 5, 170 and 197 of Amendment No. 3 to remove from registration the resale of such shares.
***
Please contact Carlos Ramirez at (858) 550-6157 or at cramirez@cooley.com or Matthew T. Browne at (858) 550-6045 or at mbrowne@cooley.com with any questions or comments regarding the Company’s response to the Staff’s Comments.
Sincerely
Cooley LLP
Show Raw Text
CORRESP
1
filename1.htm
Carlos Ramirez
T: +1 858 550 6157
cramirez@cooley.com
December 14, 2023
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Industrial Applications and Services
100 F Street, NE
Washington, D.C. 20549
Attention:
Nicholas O’Leary
Abby Adams
Re: TriSalus Life Sciences, Inc.
Amendment No. 2 to Registration Statement on Form S-1
Filed October 19, 2023
File No. 333-274292
Ladies and Gentlemen:
On behalf of TriSalus Life Sciences, Inc.
(the “Company”), we are providing this letter in response to comments (the “Comments”)
received from the staff of the U.S. Securities and Exchange Commission’s Division of Corporation Finance (the “Staff”)
by letter dated November 4, 2023 with respect to the Company’s Amendment No. 2 to Registration Statement on Form S-1,
as filed on October 19, 2023. Concurrently with the submission of this letter, the Company is filling its third amendment to the
registration statement on Form S-1 (the “Amendment No. 3”) and certain exhibits via EDGAR to the Commission.
The Staff’s comments are repeated below
in bold, followed by the Company’s responses to the comments. We have included page numbers to refer to the location in Amendment
No. 3 where the disclosure addressing a particular comment appears. Defined terms used but not otherwise defined herein shall have
the respective meanings ascribed thereto in Amendment No. 3.
Amendment No. 2 to Registration Statement on Form S-1
filed October 19, 2023
Cover Page
1. We note your revisions in response to prior comment 1 and we reissue in part. Please disclose here
any purchase price of the assumed RSUs and legacy Trisalus shares or clarify that no consideration was paid.
In response to the Staff’s comment,
the Company respectfully advises the Staff that it has revised the disclosure on the cover page and page 5 of Amendment No. 3.
In response to comment 3 below, the Company has removed from registration the resale of the legacy Trisalus shares from Amendment No.
3.
Cooley LLP 10265 Science Center
Drive San Diego, CA 92121-1117
t: +1 858 550 6000 f: +1 858 550-6420 cooley.com
U.S. Securities and Exchange Commission
December 14, 2023
Page Two
General
2. We note your analysis in response to prior comment 9, and reissue the comment in full. Please revise
the first paragraph on the cover page, and the prospectus generally, to remove the registration of the issuance of common stock underlying
the warrants referenced in the comment.
In response to the Staff’s comment,
the Company respectfully advises the Staff that it has revised the disclosure on the cover page and pages 4 and 197 of Amendment
No. 3 to remove from registration the issuance of common stock underlying the “Conversion Warrants” referenced in Amendment
No. 3. The revised disclosure takes into account the clarification provided by the Staff pursuant to a conference call on November
7, 2023 that the Staff is only reissuing the comment for the “Conversion Warrants” and not the “Private Placement Warrants.”
3. We note your revisions to prior comment 10 and we reissue the comment. The company seeks to register
“(c) up to 15,575,001 shares of Common Stock issued pursuant to that Agreement and Plan of Merger, dated as of November 11,
2022, as amended on April 4, 2023, May 13, 2023 and July 5, 2023, by and among MTAC, MTAC Merger Sub, Inc. and TriSalus
Operating Life Sciences, Inc. (‘Legacy TriSalus’) to certain former equityholders of Legacy TriSalus,” as noted
in the second paragraph on the cover page. As TriSalus merged into the SPAC merger subsidiary, these affiliates are deemed to be underwriters,
and must set a fixed price at which the shares will be sold for the duration of the offering. Refer to Securities Act Rule 145(c).
Please revise the prospectus accordingly.
In response to the Staff’s comment, the Company respectfully advises the Staff that it has revised
the disclosure on the cover page and pages 5, 170 and 197 of Amendment No. 3 to remove from registration the resale of
such shares.
***
Please
contact Carlos Ramirez at (858) 550-6157 or at cramirez@cooley.com or Matthew T. Browne at (858) 550-6045 or at mbrowne@cooley.com
with any questions or comments regarding the Company’s response to the Staff’s Comments.
Sincerely
Cooley LLP
/s/ Carlos Ramirez
Carlos Ramirez
cc: Mary Szela - TriSalus Life Sciences, Inc.
Matthew T. Browne - Cooley LLP
Cooley LLP 10265 Science Center
Drive San Diego, CA 92121-1117
t: +1 858 550 6000 f: +1 858 550-6420 cooley.com